Abstract
AbstractIn this commentary, we discussed the important role of intratumoural specific T‐cell receptor (TCR) β chain rearrangements on tumour‐infiltrating lymphocytes in predicting clinical outcomes of adjuvant tyrosine kinase inhibitor therapy or chemotherapy in patients with non‐small‐cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutation from two aspects. The in‐depth study of the local immune microenvironment may help to discover possible biomarkers for predicting the overall survival and disease‐free survival and may further direct to select of the appropriate adjuvant therapy in EGFR‐mutant NSCLC patients according to the special TCR rearrangements.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
